Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 3/20 | 0.40 |
| ▸ | TACR2 | P21452 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 7/20 | 0.37 |
| ▸ | MAOA | P21397 | 4/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10088536 | 0.88 | CSNK2A1 (0.40) | MAOBMAOALMNA | |
| SCHEMBL10088654 | 0.87 | MAOB (0.35) | MAOBMAOASMN1; SMN2GRM5NPC1 | |
| SCHEMBL10088973 | 0.87 | PPARA (0.37) | MAOBMAOASMN1; SMN2NPC1RAB9A | |
| SCHEMBL10088608 | 0.86 | MAOB (0.40) | MAOBMAOASMN1; SMN2GRM5L3MBTL1 | |
| SCHEMBL10088605 | 0.85 | FFAR1 (0.38) | FFAR1MAOBMAOASMN1; SMN2NPC1 | |
| SCHEMBL10088609 | 0.85 | CSNK2A1 (0.44) | MAOBMAOAGRM5 | |
| SCHEMBL10088603 | 0.85 | S1PR1 (0.46) | MAOBMAOASMN1; SMN2GRM5NPC1 | |
| SCHEMBL10088469 | 0.84 | RORC (0.36) | MAOBMAOASMN1; SMN2GRM5NPC1 | |
| SCHEMBL10088535 | 0.83 | TACR2 (0.37) | FFAR1TACR2LMNASMN1; SMN2NPC1 | |
| SCHEMBL10088563 | 0.81 | MAOB (0.41) | MAOBMAOASMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2012-07-12 | — | — | US | disclosed |
| US-8193378-B2 | 2H-chromene compound and derivative thereof | ASTELLAS PHARMA INC. (JP) | 2012-06-05 | — | — | US | disclosed |
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | ASTELLAS PHARMA INC. (JP) | 2011-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110230463-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, CCR1 | FFAR1 73/4885TACR2 241/4885MAOB 2521/4885 |
| US-20120178735-A1 | 2H-CHROMENE COMPOUND AND DERIVATIVE THEREOF | S1PR1, S1PR2, S1PR4 | FFAR1 42/4885TACR2 285/4885MAOB 3106/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.